Subjective experiences of schizophrenic patients treated with antipsychotic medication

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Neuroleptics; Quality of life; Self rating scale; Subjective side effects

Indexed keywords

CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AFFECTIVE NEUROSIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MOOD; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SELF CONCEPT; TECHNIQUE; WELLBEING;

EID: 0031905835     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199801001-00007     Document Type: Conference Paper

References (15)

1. Gebhardt R (1972). Investigation of the subjective well-being of psychotic patients under neuroleptic therapy [in German]. Pharmacopsychiatry 5:295-300.
2. Helmchen H, Hippius H (1969). Pharmacogenic depression [in German]. In: The depressive syndrome [in German]. Hippius H, Selbach H (editors). Munich: Schattauer. pp. 443-448.
3. Hogan TP, Awad AG, Eastwood R (1983). A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177-183.
4. Jaeger J, Bitter I, Czobor P, Volavka J (1990). The measurement of subjective experience in schizophrenia: the subjective deficit syndrome scale. Compr Psychiatry 31:216-226.
5. Lader M (1993). Neuroleptic induced deficit syndrome: old problem, new challenge. J Clin Psychopharmacol 7:392-393.
6. Liddle PF, Barnes TRE (1988) .The subjective experience of deficits in schizophrenia. Compr Psychiatry 29:157-164.
7. Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 4:892-897.
8. Naber N (1995). A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int J Psychopharmcol 10 (suppl 3):S133-S138.
9. Naber D, Gaussares C, Moeglen JM, Tremmel I, Bailey PE (1992a). Efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia. In: Novel antipsychotic drugs. Meltzer H (editor). New York: Raven Press, pp. 99-107.
10. Naber D, Holzbach R, Perro C, Hippius H (1992b). Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 (suppl 17):54-59.
11. Naber D, Walther A, Kircher T, Hayek D, Holzbach R (1994). Subjective effects of neuroleptics predict compliance. In: Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Gaebel W, Ward AG (editors). Vienna: Springer, pp. 85-98.
12. Rifkin A, Quitkin F, Klein DF (1975). Akinesia: a poorly recognized drug-induced extrapyramidal behavioural disorder. Arch Gen Psychiatry 32:672-674.
13. Selten JP, Sijben NES, van den Bosch RJ (1993). The subjective experience of negative symptoms: a self-rating scale. Compr Psychiatry 34:192-197.
14. Van Putten T (1978). Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 35:1101-1107.
15. Wise RA (1991). Neuroleptic-induced anhedonia. Recent studies. In: Advances in neuropsychiatry and psychopharmacology, vol 1: Schizophrenia research. Tamminga CA, Schulz SC (editors). New York: Raven Press, pp. 323-331.